Evaluation of the Effectiveness of Botulinum Neurotoxin A Injections for Pediatric Spastic Cerebral Palsy

Spastic cerebral palsy is a neurological condition caused by brain damage to the fetal or newborn brain, with damage centralized to the motor cortex. Impaired neurons in the cortex transmit constant nerve impulses to skeletal muscle, causing many voluntary movements to become spastic contractions. There are a plethora of treatments for spasticity, but occupational therapy (OT) proves to be among the most effective of treatment strategies. However, a recent treatment for spastic cerebral palsy is Botulinum Neurotoxin A (BoNT-A) injections. BoNT-A is a neuromuscular blocker that prevents the release of acetylcholine from the motor nerve axon, temporarily paralyzing the muscle fibers for up to 3 months depending on dose strength and volume. According to current key clinical studies, OT following injections may optimize limb function and reduce the need for recurrent injections. This clinical review analyzed the safety and efficacy of upper-limb injection of BoNT-A and compared BoNT-A to OT treatment for pediatric spastic cerebral palsy. Efficacy and safety of repeat BoNT-A injections were evaluated using the Modified Ashworth Scale and vital sign measures, assessing spasticity and general health in children with spastic cerebral palsy receiving repeat injections. Researchers concluded that BoNT-A injections are a safe treatment for patients and significantly reduce upper-limb spasticity. Additionally, BoNT-A injections combined with pediatric OT treatment were compared with OT alone in a 12-month randomized controlled trial. Outcome measures included range of motion tests and occupational performance measures, and results demonstrated that BoNT-A as an adjunct to OT led to significantly greater function during daily upper extremity tasks compared to OT treatment alone. Finally, a systematic review and meta analysis further demonstrated the effectiveness of BoNT-A injections for reduction in spasticity and functional improvements in children with spastic cerebral palsy; however, OT combined with BoNT-A treatment significantly optimized results. In conclusion, this literature review showed that BoNT-A is best used as an adjunct to OT, reducing spasticity and increasing functional performance of the affected limbs. Future research directions include investigation of the sustained treatment effects of BoNT-A over the long term along with the efficacy of BoNT-A for fixed contractures.